. home.aspx



Atomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership

September 12, 2019 / GEN

Atomwise and Jiangsu Hansoh Pharmaceutical Group—the Chinese company behind this year’s largest biopharma initial public offering (IPO)—said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for up to 11 undisclosed target proteins in cancer and “multiple” other therapeutic areas. The collaboration is intended to combine Atomwise’s AI technology, medicinal chemistry, and protein structure expertise with Hansoh Pharma’s fully integrated R&D, manufacturing, and commercial capabilities, with the aim of accelerating and improving drug discovery and clinical development, Atomwise said. Atomwise uses AI for its structure-based, drug design technology, which is based on convolutional neural networks along the lines of those that recognize faces in a crowd or enable self-driving cars. Atomwise’s AI technology is designed to enable scientists to predict how well a small molecule will ...